NCT06167785 - A Study to Evaluate Zanubrutinib and Tislelizumab in Progressive Lymphoma Post CAR-T | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 4, 2025

Primary Completion Date

April 30, 2026

Study Completion Date

December 31, 2027

Conditions

Large B-cell Lymphoma

Interventions

DRUG

Tislelizumab

Tislelizumab 200mg intravenously every 3 weeks

DRUG

Zanubrutinib

Zanubrutinib 160 mg oral twice daily

DRUG

Tislelizumab + Zanubrutinib

Tislelizumab 200mg intravenously day 1 of each cycle every 3 weeks + Zanubrutinib 160 mg oral twice daily starts day 1 of each cycle

Trial Locations (1)

RECRUITING

University Health Network (UHN), Toronto

All Listed Sponsors

lead

University Health Network, Toronto

OTHER